Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers

Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers

Abstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific...

Full description

Saved in:
Bibliographic Details
Main Authors: Hannes Vietzen, Laura M. Kühner, Sarah M. Berger, Markus Ponleitner, Marianne Graninger, Charlotte Pistorius, Christof Jungbauer, Markus Reindl, Henrieke Saucke, Franziska Kauth, Eva-Maria Wendel, Kevin Rostásy, Markus Breu, Barbara Kornek, Gabriel Bsteh, Thomas Berger, Paulus Rommer, Elisabeth Puchhammer-Stöckl
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-61751-9
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS.
ISSN:2041-1723

Similar Items